InsidersTradesSigma
申报总数
公司
▲ 买入（2 笔）
▼ 卖出（0 笔）
内部人交易记录
首席执行官已披露买入
2
已披露卖出
0
尚无足够的、已确定 T+90 期限的买入信号来衡量交易记录。
信号历史
Discover the complete record of transactions filed by Rombotis Spiro George, 首席执行官. Insider active across 1 company, notably Cyclacel Pharmaceuticals, Inc.. Cumulatively, 3 disclosures have been recorded. Breakdown: 2 buys · 0 sell. Total volume traded: €34k. Activity tracked since 18 November 2021. The latest transaction was filed on 21 December 2023 (Acquisition). Regulator: SEC (Form 4). The full history is accessible without signup.
Companies and markets linked to Rombotis Spiro George
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
申报3 总计
6,070 股@ US$3.31536.6% 占其流量Common StockSEC:0001104659-23-129185:0
标准退出：2024年3月20日 (T+90)
57,600 股0Common StockSEC:0001104659-23-009910:0
4,000 股@ US$4.5046.4% 占其流量Common StockSEC:0001104659-21-142474:0
标准退出：2022年2月16日 (T+90)
3 条申报中的 3 条
About Rombotis Spiro George
Spiro George Rombotis serves as President and CEO of Cyclacel Pharmaceuticals, Inc. He leads the strategic operations and ensures the growth of the company. His leadership is essential in advancing Cyclacel's mission, which focuses on developing innovative treatments. With extensive experience in the biopharmaceutical sector, Mr. Rombotis plays a key role in innovation and enhancing healthcare services.
